The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to ...
ICON expects market conditions to remain similar through year-end, assuming persistent cancellation rates and mixed timing on biotech conversions. The company raised its full year revenue guidance to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback